When eosinophilic asthma
aim for power,
FASENRA is an add-on maintenance treatment for patients 12 and up with severe eosinophilic asthma.1
FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
FASENRA is not indicated for treatment of other eosinophilic conditions.
FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus.
FASENRA is the only respiratory biologic that combines Q8W maintenance dosing* with at-home or in-office administration options and offers patients the fewest injections per year.1
*Every 8 weeks following the first 3 doses Q4W.1
Talk to your patients about which administration option is most convenient for them.
- FASENRA is intended for use under the guidance of a healthcare professional. In line with clinical practice, monitoring of patients after administration of biologic agents is recommended1
- Patients/caregivers may administer with FASENRA Pen after proper training in subcutaneous injection technique and after healthcare professional determines it is appropriate1
Dosing comparisons do not imply comparable efficacy, safety, or FDA-approved indications.
YOU ARE ABOUT TO LEAVE FASENRA.COM
Please note: AstraZeneca does not control, review, or endorse third-party content and is not responsible for the content you are about to access. We provide links to external Web sites as a convenience and for educational purpose only.
Would you like to continue to an external link?